Physician profile
Brian J Feinstein
NPI 1780802595
$7,540.46
in general payments reported to CMS, 2019-2025
24 companies · $5,335 in 2025
The $5,335 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.68 · 2020: $77.72 · 2021: $275 · 2022: $413 · 2023: $761 · 2024: $632 · 2025: $5,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,550 · Food and Beverage: $2,148 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,550.00 |
| Food and Beverage | $2,148.10 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,489.62 | 2020-2025 | |
| Genzyme Corporation | $282.68 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $245.40 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $168.98 | 2021-2025 | |
| Galderma Laboratories, L.P. | $166.40 | 2020-2025 | Nemluvio |
| Amgen INC. | $163.22 | 2022-2024 | Otezla |
| Janssen Biotech, INC. | $157.54 | 2022-2025 | Tremfya |
| Allergan, INC. | $157.18 | 2020-2022 | |
| Ucb, INC. | $133.76 | 2024-2025 | Bimzelx |
| Pfizer INC. | $116.77 | 2022-2025 | |
| Incyte Corporation | $110.92 | 2023-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.08 | 2022-2023 | Spevigo |
| Sun Pharmaceutical Industries INC. | $49.58 | 2020-2023 | Ilumya |
| Strata Skin Sciences, INC. | $40.01 | 2022-2025 | Xtrac |
| Almirall LLC | $34.07 | 2022-2025 | Klisyri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $29.82 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $25.21 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $23.86 | 2019 | |
| Leo Pharma INC. | $23.82 | 2025 | Anzupgo |
| Dusa Pharmaceuticals, INC. | $21.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.72 | 2024 | Sotyktu |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.